Tagged With "AAAAI"

Blog Post

AAFA CEO Shares Patient Concerns About Restrictions to Allergen Immunotherapy

AAFA Community Services ·
AAFA does not support the changes proposed by USP because we believe they pose a real threat to quality of care. We strongly urge the USP to keep existing guidelines for allergen immunotherapy in place so that millions of patients across the United States can continue to receive the treatment they need.
Blog Post

Join Us for a Spring Allergies Twitter Party

AAFA Community Services ·
Are you on Twitter? Join the Asthma and Allergy Foundation of America @AAFANational Wednesday, March 30 at 7 pm for a Spring Allergies Twitter Party! The chat is hosted by the American Academy of Allergy, Asthma & Immunology and Allergic Living. Follow @AAAAI_org and @AllergicLiving and use #allergyready. Post questions about hay fever, pollen troubles and other spring allergy topics. The AAAAI Allergist Panel includes: Dr. Thanai Pongdee @Tpongdee Dr. Matthew Bowdish @MatthewBowdish Dr.
Blog Post

Omalizumab Could Help Children with Asthma Fight Colds

AAFA Community Services ·
New research shows omalizumab to be a promising treatment or prevention option for virus-induced asthma exacerbations, an important public health issue that affects every child with asthma.
Blog Post

Poverty Widens Gap in Care for Asthma and Allergies

AAFA Community Services ·
Press Release Contact: Melissa Graham mgraham@aaaai.org (414) 272-6071 Onsite Press Room (March 4-7): (213) 743-6242 POVERTY WIDENS GAP IN CARE FOR ASTHMA AND ALLERGIES Researchers Examine Socioeconomic Disparities at AAAAI Annual Meeting Los Angeles, CA – Socioeconomic disparities are a cause for concern in patients with asthma and allergies, according to several studies presented at the AAAAI Annual Meeting. “We found that patients who have asthma and come from lower income households –...
Blog Post

Sign the Petition to Save Patient Access to Allergy Shots

AAFA Community Services ·
Proposed regulations introduced by the United States Pharmacopeia (USP) could dramatically limit patient access to allergen immunotherapy (allergy shots). If these new regulations go into effect, allergists would unlikely be able to continue to mix allergen extracts for their patients. The result may limit timelines of allergy shot treatment. The insurance coverage of this treatment may also be restricted. What can I do to prevent these regulations from going into effect? The American...
Blog Post

Join AAFA, AAAAI for a #TackleAsthma Twitter Chat May 5 

AAFA Community Services ·
Join the Asthma and Allergy Foundation of America and the American Academy of Allergy, Asthma & Immunology Thursday, May 5 at 1 pm ET for a #TackleAsthma Twitter chat. Follow @AAFANational and @AAAAI_org and use #TackleAsthma. Experts will answer your questions about exercising with asthma, staying fit and healthy with asthma and more!
Blog Post

Black Children Six Times More Likely to Die of Asthma

AAFA Community Services ·
There is no cure for asthma, but with the proper diagnosis, medication and an asthma management plan, symptoms can be controlled. When not properly controlled asthma can be deadly. A study being presented at the 2017 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting called “Where Do Children with Asthma Die? A National Perspective from 2003 to 2014” seeks to address where and which demographics of children are dying because of asthma in the United States.
Blog Post

Study Reviews Safety of Subcutaneous and Sublingual Allergen Immunotherapy

AAFA Community Services ·
Researchers analyzed 8 years of data and found that while overall systemic reactions have been declining, people with asthma were most at risk for them. Also no local skin infections or serious infections from injections were reported in 9.5 million injection visits.
Blog Post

GlaxoSmithKline Study Shows Nucala Improves Quality of Life, Lung Function in Severe Asthma

AAFA Community Services ·
GlaxoSmithKline plc (LSE/NYSE:GSK) today announced data demonstrating that severe asthma patients, whose disease is driven by eosinophilic inflammation, treated with first-in-class biologic Nucala® (mepolizumab) added-on to standard of care, achieved clinically and statistically significant improvements in their health-related quality of life and lung function, when compared to patients treated with placebo and standard of care. These results are from the phase IIIb MUSCA study (NCT02281318, 200
×
×
×
×